Search results for " neuroprotection"

showing 5 items of 35 documents

Mildronate as a Regulator of Protein Expression in a Rat Model of Parkinson’s Disease

2011

Background. Mildronate (3-[2,2,2-trimethylhydrazinium] propionate dihydrate) traditionally is a well-known cardioprotective drug. However, our recent studies convincingly demonstrated its neuroprotective properties. The aim of the present study was to evaluate the influence of mildronate on the expression of proteins that are involved in the differentiation and survival of the nigrostriatal dopaminergic neurons in the rat model of Parkinson’s disease (PD). The following biomarkers were used: heat shock protein 70 (Hsp70, a molecular chaperone), glial cell line-derived nerve growth factor (GDNF, a growth factor promoting neuronal differentiation, regeneration, and survival), and neural cell …

biologybusiness.industryGrowth factormedicine.medical_treatmentSubstantia nigraGeneral MedicineStriatumPharmacologyNeuroprotectionHsp70Nerve growth factornervous systemmedicineGlial cell line-derived neurotrophic factorbiology.proteinmildronate; protein expression; neuroprotectionNeural cell adhesion moleculebusinessMedicina
researchProduct

Will it ever become possible to prevent dopaminergic neuronal degeneration?

2008

Parkinsons disease (PD) is the second leading age-related degenerative brain disease in the world affecting millions of people. This neurological disorder disrupts the quality of life of patients and their families, exerts an enormous emotional and physical strain on caregivers, and has a large cost for society. Moreover, the increasing numbers of elderly people in the population will result in a sharp increase in the prevalence of PD. The understanding of its pathophysiology and treatment has advanced at a very impressive rate during past decades. Nevertheless, PD is still fatal and there is at present no cure for it. Furthermore, there are no proven therapies for prevention of PD and alth…

medicine.medical_specialtyDopaminePopulationNeurological disorderDiseaseNeuroprotectionSettore BIO/09 - FisiologiaNeuroprotective agentsRisk FactorsmedicineAnimalsHumansNeuronal degenerationNeurodegeneration Neuroprotection Parkinson's diseaseIntensive care medicineeducationPharmacologyNeuronseducation.field_of_studyCell Deathbusiness.industryGeneral NeuroscienceDopaminergicNeurodegenerative DiseasesParkinson's disease -- Treatmentmedicine.diseaseBrain diseaseNeuroprotective AgentsDrug developmentbusinessNervous system -- Degeneration
researchProduct

Japanese, Mediterranean and Argentinean diets and their potential roles in neurodegenerative diseases

2019

Environmental factors are responsible of cellular senescence and processes found in the development of cognitive disorders. The aim of this paper is to compare benefits of the Japanese, Mediterranean, and Argentinian Diet on the onset or prevention of senile dementia (SD) and Alzheimer's Disease (AD). Special focus was on the effects of specific compounds such as polyunsaturated fatty acids (PUFAs), antioxidants, and saturated and trans fatty acids. A high adherence to diets rich in PUFAs, monounsaturated fatty acids (MUFAs) and antioxidants may decrease the risk of developing neurodegenerative diseases ; while the predominance of saturated and trans fatty acids possibly rises it.

medicine.medical_specialtyMediterranean diet030309 nutrition & dieteticsArgentinaCellular senescenceDiseaseBiologySenile dementiaDiet MediterraneanNeuroprotection03 medical and health sciences0404 agricultural biotechnologyJapanAlzheimer DiseaseInternal medicinealzheimer's disease ; neuroprotection ; mediterranean diet ; japanese style diet ; food patternmedicineHumanschemistry.chemical_classification0303 health sciencesMediterranean RegionNeurodegenerative Diseases04 agricultural and veterinary sciences040401 food scienceNeuroprotectionDietEndocrinologychemistryFatty Acids UnsaturatedDementiaFood SciencePolyunsaturated fatty acidFood Research International
researchProduct

Erythropoietin for Subarachnoid Hemorrhage: Is There a Reason for Hope?

2011

I b S a r a S ubarachnoid hemorrhage (SAH) associated with a ruptured cerebral aneurysm remains a source of significant morbidity and mortality, not only from the initial hemorrhage but lso from the delayed complications, such as cerebral vasospasm ften severe enough to induce irreversible changes in cerebral erfusion. Several drugs have been developed that have the otential to limit cerebral vasospasm and delayed ischemic eurologic deficit, thus improving outcome for patients. Howver, although numerous agents that can prevent arterial narrowng and/or block the excitatory cascade of events leading to schemic neuronal death in experimental conditions, there is still o pharmacologic agent tha…

medicine.medical_specialtySubarachnoid hemorrhageErythropoietin subarachnoid hemorrhageBlood volumeAneurysm RupturedNeuroprotectionAneurysmCerebral vasospasmInternal medicinemedicineErythropoietin; Neuroprotection; Subarachnoid hemorrhageHumansSubarachnoid hemorrhageErythropoietinSettore MED/27 - Neurochirurgiabusiness.industryEpoetin alfaPharmacologic Agentmedicine.diseaseRecombinant ProteinsNeuroprotectionEpoetin AlfaNeuroprotective AgentsErythropoietinCardiologySurgeryNeurology (clinical)businessmedicine.drug
researchProduct

Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms

2007

In the present work we reviewed recent advances concerning neuroprotective/neurotrophic effects of acute or chronic nicotine exposure, and the signalling pathways mediating these effects, including mechanisms implicated in nicotine addiction and nAChR desensitization. Experimental and clinical data largely indicate long-lasting effects of nicotine and nicotinic agonists that imply a neuroprotective/neurotrophic role of nAChR activation, involving mainly alpha 7 and alpha 4 beta 2 nAChR subtypes, as evidenced using selective nAChR agonists. Compounds interacting with neuronal nAChRs have the potential to be neuroprotective and treatment with nAChR agonists elicits long-lasting neurotrophic e…

neuroplasticitydesensitizationFGF-2nAChRReceptors NicotinicBiologyPharmacologySettore BIO/09 - FisiologiaNeuroprotectionNicotineNeurotrophic factorsmedicineAnimalsHumansnicotinic agonistNerve Growth FactorsNicotinic Agonistsneurotrophic factorBiological PsychiatryNeuronal PlasticitynAChR; nicotinic agonists; neurotrophic factors; FGF-2; neuroprotection; neurotrophism; addiction; desensitization; neuroplasticityBrainNeurodegenerative DiseasesTobacco Use DisorderPsychiatry and Mental healthNeuroprotective AgentsNerve growth factorNicotinic agonistNeurologySynaptic plasticityneurotrophismbiology.proteinneuroprotectionaddictionNeurology (clinical)Signal transductionNeuroscienceSignal Transductionmedicine.drugNeurotrophinJournal of Neural Transmission
researchProduct